Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023
April 21, 2023 01:00 ET
|
Pixium Vision
Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023 Paris, April 21, 2023 – 7.00 a.m. CET - Pixium...
Communication faisant suite à l’annonce de l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche
April 03, 2023 01:00 ET
|
Pixium Vision
Communication faisant suite à l’annonce de l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche Conversion de 160 ORNAN2022 par ESGO...
Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMD
April 03, 2023 01:00 ET
|
Pixium Vision
Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMD Conversion of 160 ORNAN2022 by ESGO with intention to pursue controlled trading...
Pixium Vision annonce l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche
March 31, 2023 01:00 ET
|
Pixium Vision
Pixium Vision annonce l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche Pixium Vision et la FDA collaboreront étroitement pendant la phase...
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD
March 31, 2023 01:00 ET
|
Pixium Vision
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Pixium Vision to receive interactive communication with FDA through premarket review phase of Prima System...
Réduction du capital social motivée par des pertes par réduction de la valeur nominale: nombre d’actions inchangé
March 17, 2023 02:00 ET
|
Pixium Vision
Réduction du capital social motivée par des pertes par réduction de la valeur nominale : nombre d’actions inchangé Paris, France, 17 mars 2023 – 7 h CET– Le Conseil d’administration de la Société a...
Reduction of share capital due to losses by reduction of nominal value: number of shares unchanged
March 17, 2023 02:00 ET
|
Pixium Vision
Reduction of share capital due to losses by reduction of nominal value: number of shares unchanged Paris, France, March 17, 2023 – 07:00 CET – The Board of Directors of the Company decided at its...
Assemblée Générale Extraordinaire du 8 mars 2023 résultats
March 10, 2023 13:00 ET
|
Pixium Vision
Assemblée Générale Extraordinaire du 8 mars 2023 résultats Paris, France, 10 mars 2023 – 19 h CET– L’Assemblée Générale Extraordinaire des actionnaires de Pixium Vision SA (Euronext Growth Paris -...
Results of Extraordinary Shareholders Meeting held on March 8, 2023
March 10, 2023 13:00 ET
|
Pixium Vision
Results of Extraordinary Shareholders Meeting held on March 8, 2023 Paris, France,March 10, 2023 – 19:00 CET – The Extraordinary Shareholders Meeting of Pixium Vision SA (Euronext Growth Paris -...
Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documents
February 28, 2023 13:00 ET
|
Pixium Vision
Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documents Paris, France, February 28, 2023 – 19.00 am CET – Pixium Vision SA (Euronext Growth Paris -...